Efficacy of Autologous Serum Therapy in patients with Chronic Urticaria

Authors

  • Boshra Wannous Tishreen university
  • Mohamad Adel Ismaiel Tishreen University
  • Jamal Khaddam Tishreen University

Abstract

Objective: To evaluate the efficacy of Autologous Serum Therapy (AST) in patients with Chronic Urticaria and compare the efficacy of AST in both Autologous Serum Skin Test (ASST) positive and negative groups.

Settings and design: A prospective study (before & after).

Methods and materials: We enrolled 50 patients suffering from Chronic Urticaria. ASST was done in all patients. Autologous serum was given intramuscularly weekly for 9 weeks. The effect of AST was evaluated by using Urticaria Total Severity Score (UTSS) at baseline (0 weeks), at the end of the treatment (9 weeks), and followed up for 3 months after the end of the treatment (21 weeks).

Results: Among 50 patients, ASST was positive in 25 patients (50%) and negative in 25 patients (50%). 18 patients (36%) had an excellent improvement, 7 patients (14%) had a very good improvement, 11 patients (22%) had a good improvement, and 14 patients (28%) had no improvement. The treatment was effective in both ASST positive and negative groups, however there was no significant relationship in improvement between two groups. The patients with excellent improvement were in ASST (+) group (52%) more than ASST (-) group (20%), and it was statistically significant (p-value=0.02). There was a significant relationship between clinical improvement and severity of disease (p-value = 0.04), the majority of excellent improvement cases (88.9%) had severe disease before the treatment.

Conclusion: AST was effective in the treatment of Chronic Urticaria with no side effects. The treatment was effective in both ASST (positive and negative) groups.

Author Biographies

Boshra Wannous, Tishreen university

Postgraduate Student, Depatment of Dermatology, Faculty of Medicine

Mohamad Adel Ismaiel, Tishreen University

Professor, Depatment of Dermatology, Faculty of Medicine

Jamal Khaddam, Tishreen University

Associate Professor, Depatment of Dermatology, Faculty of Medicine

Downloads

Published

2022-07-31

How to Cite

1.
ونوس ب, محمد عادل اسماعيل, جمال خدام. Efficacy of Autologous Serum Therapy in patients with Chronic Urticaria. Tuj-hlth [Internet]. 2022Jul.31 [cited 2024Dec.25];44(3):213-22. Available from: https://journal.tishreen.edu.sy/index.php/hlthscnc/article/view/12317

Issue

Vol. 44 No. 3 (2022): Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

Section

Master student researches

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

 Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series   .  The Readers have the right to send, print and subscribe to the initial version of the article, and the title of  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series  Publisher

journal uses a CC BY-NC-SA license which mean

You are free to:

  • Adapt — remix, transform, and build upon the material
  •  
  • The licensor cannot revoke these freedoms as long as you follow the license terms.

 

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.